CVS CVS Health Corp

$CVS $SPY $125 easily at upcoming earnings with Buyback News. Buybacks…. • It still has authorized programs in place: the $10 billion 2022 Repurchase Program (fully remaining) and about $1.5 billion remaining under the 2021 program (as of mid-2026).  CFO Brian Newman has said the company is getting closer to restarting buybacks (previously targeted for 2027 after balance-sheet repair) and will provide an update later in 2026 on whether that could happen sooner.

$CVS - they received almost more than 85% with 4 plus ratings …might rally tomorrow along with $HUM

$CVS relax people Usually after touching ATH double tops, retesting previous support levels is normal. It has to prove itself. And it will.

$CVS people are spam posting this stock for some reason lol. Unlike $HOUR who has crazy numbers to back it up.

$CVS This is straight from the 2027 update. It’s bad. “Yes — straight from the CMS file. The ugly ones: - **H5325** (Coventry Kansas): 4.5 → **3.0** - **H3959** (PA HMO, 235K members): 4.5 → **3.5** - **H2663, H1692, H5302, H3928**: all 4.5 → **3.5** And 3.5 is the real cliff — that's below the 4.0 bonus threshold, so those contracts lose the entire 5% quality bonus *and* drop to a 60% rebate share. The 3.0 is even worse at 50%. These aren't rounding errors; they're hundreds of thousands of members falling off the bonus map entirely.“

$CVS the last 5 days there has been a volume spike at 3:45 pm taking cvs down there is a lot of puts for friday today 88 87 86 but nothing for 85 so i think we hit bottom but watching the 3:45 volume

$CVS - safest stock to own with strong dividend and cash flow…near term 94 by Friday…way oversold…imo

$CVS Deeply oversold in uptrend. Many consecutive earnings beat and raises. 415 Billion in revenue. 11 times forward. 3 Percent dividend Healthcare behemoth Incredible long term buy 150 buck value

$CVS Mini pharmacy concept will be profitable as high margin meds including over the counter will bloom Walgreen stores will become mini CVS HEALTH CORP

🟢 $CVS $93 CALL — 10/16 EXP @ $0.09 🎯 🔥 Cheap contract with lotto potential! Keep position size small and manage your risk. 📈

$CVS recently added this to my watch list. Every time I opened this stock I saw hearts and was like “wow people are really friendly here” until I realized that the heart is their logo and not an emoji.

$CVS - next week earnings from $UNH will rally whole sector . $CVS might rally above 95 next week…way oversold near term

$CVS — CVS Health's strategic shift to value-based care and Medicare plan adjustments were central to recent analyses, alongside pharmaceutical distribution agreements.

$CVS looks ready for a PREMILINARY POSITION! 50WMA has been respected, but a breakout is only confirmed at $90 If the $80 support area is revisited, that's the spot to load up!

$CVS: in Smith v. Aetna, the suit alleges the prerecorded 'Aetna Better Health' call was addressed to someone else: same first name, different surname, Mar 17, 2025. Aetna has not responded. Nothing to claim. Open Class Actions.

$CVS: in-store shopping alone does not qualify. The suit alleges site and app tech shared private data. US digital access before July 27 counts, up to $5 no proof, one per household, claim by Nov 16. Open Class Actions.

$CVS: bought the Well Market Replenish mix in Watermelon? That Fresno purchase is at the center of Colby v. CVS, filed Oct 1 in Rhode Island. It alleges a price premium for "ZERO SUGAR" claims. Nothing to claim yet. Open Class Actions.

$CVS SimplyWallstreet said Most Popular Narrative: 29% Undervalued Against the last close of $87.55, the most followed narrative pegs CVS Health’s fair value at $124, which frames the current pullback as a potential pricing gap rather than a verdict on the whole business

🔴 $CVS 87P Oct 16 💰 $75,300 premium 💵 $1.48/contract 📊 1.5x Vol/OI 📍 Spot $86.59 🚨 Repeat sweep 🌊 Dark Flow | Options Flow

CVS Pharmacy and its corporate affiliates have agreed to pay $315 million to settle allegations of illegally dispensing controlled substances and fraudulently billing federal healthcare programs over a 12-year period. The civil settlement resolves a US Department of Justice lawsuit filed in Rhode Island concerning dispensing practices between October 2013 and December 2025. Prosecutors alleged that CVS repeatedly filled invalid prescriptions for dangerous opioid quantities, early refills and potentially abusive drug combinations. The government claimed internal performance targets, incentive-based compensation and chronic understaffing encouraged pharmacists to overlook warning signs involving suspicious prescribers. Beyond the financial penalty, CVS signed an agreement with the Drug Enforcement Administration (DEA) requiring stronger compliance safeguards across its pharmacy network. $CVS